PharmaResources (Shanghai) Co. Ltd. A (301230) - Net Assets
Based on the latest financial reports, PharmaResources (Shanghai) Co. Ltd. A (301230) has net assets worth CN¥1.03 Billion CNY (≈ $150.71 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.32 Billion ≈ $192.55 Million USD) and total liabilities (CN¥285.89 Million ≈ $41.83 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 301230 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.03 Billion |
| % of Total Assets | 78.27% |
| Annual Growth Rate | 30.72% |
| 5-Year Change | 188.21% |
| 10-Year Change | N/A |
| Growth Volatility | 86.66 |
PharmaResources (Shanghai) Co. Ltd. A - Net Assets Trend (2020–2025)
This chart illustrates how PharmaResources (Shanghai) Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See 301230 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for PharmaResources (Shanghai) Co. Ltd. A (2020–2025)
The table below shows the annual net assets of PharmaResources (Shanghai) Co. Ltd. A from 2020 to 2025. For live valuation and market cap data, see market cap of PharmaResources (Shanghai) Co. Ltd. A.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.00 Billion ≈ $146.95 Million |
-2.76% |
| 2024-12-31 | CN¥1.03 Billion ≈ $151.12 Million |
-7.59% |
| 2023-12-31 | CN¥1.12 Billion ≈ $163.53 Million |
+0.42% |
| 2022-12-31 | CN¥1.11 Billion ≈ $162.85 Million |
+219.39% |
| 2021-12-31 | CN¥348.44 Million ≈ $50.99 Million |
+32.40% |
| 2020-12-31 | CN¥263.18 Million ≈ $38.51 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PharmaResources (Shanghai) Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 80.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥109.84 Million | 10.94% |
| Other Components | CN¥894.39 Million | 89.06% |
| Total Equity | CN¥1.00 Billion | 100.00% |
PharmaResources (Shanghai) Co. Ltd. A Competitors by Market Cap
The table below lists competitors of PharmaResources (Shanghai) Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kardemir Karabuk Demir Celik Sanayi ve Ticaret AS Class D
IS:KRDMD
|
$706.34 Million |
|
Sijin Intelligent Forming Machinery
SHE:003025
|
$706.37 Million |
|
Media and Games Invest PLC
F:M8G
|
$706.46 Million |
|
COSCO SHIPPING Technology Co Ltd
SHE:002401
|
$706.48 Million |
|
Anhui Ronds Science & Technology Inc Co
SHG:688768
|
$706.09 Million |
|
Propel Holdings Inc
TO:PRL
|
$706.01 Million |
|
Zhejiang Yasha Decoration Co Ltd
SHE:002375
|
$705.90 Million |
|
Shanghai Chuangli Group Co Ltd
SHG:603012
|
$705.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PharmaResources (Shanghai) Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,032,697,458 to 1,004,230,108, a change of -28,467,350 (-2.8%).
- Net income of 34,294,767 contributed positively to equity growth.
- Dividend payments of 54,044,723 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥34.29 Million | +3.42% |
| Dividends Paid | CN¥54.04 Million | -5.38% |
| Other Changes | CN¥-8.72 Million | -0.87% |
| Total Change | CN¥- | -2.76% |
Book Value vs Market Value Analysis
This analysis compares PharmaResources (Shanghai) Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.81x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.78x to 4.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥2.51 | CN¥34.58 | x |
| 2021-12-31 | CN¥3.32 | CN¥34.58 | x |
| 2022-12-31 | CN¥7.95 | CN¥34.58 | x |
| 2023-12-31 | CN¥7.99 | CN¥34.58 | x |
| 2024-12-31 | CN¥7.40 | CN¥34.58 | x |
| 2025-12-31 | CN¥7.19 | CN¥34.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PharmaResources (Shanghai) Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.98%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.31x
- Recent ROE (3.42%) is below the historical average (9.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 18.50% | 17.21% | 0.76x | 1.42x | CN¥22.37 Million |
| 2021 | 21.12% | 16.42% | 0.80x | 1.60x | CN¥38.73 Million |
| 2022 | 6.04% | 14.03% | 0.37x | 1.17x | CN¥-44.11 Million |
| 2023 | 3.37% | 7.68% | 0.33x | 1.33x | CN¥-74.14 Million |
| 2024 | 1.65% | 3.14% | 0.41x | 1.27x | CN¥-86.19 Million |
| 2025 | 3.42% | 4.98% | 0.52x | 1.31x | CN¥-66.13 Million |
Industry Comparison
This section compares PharmaResources (Shanghai) Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,212,589,599
- Average return on equity (ROE) among peers: 2.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PharmaResources (Shanghai) Co. Ltd. A (301230) | CN¥1.03 Billion | 18.50% | 0.28x | $706.33 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $1.40 Billion | -0.26% | 0.06x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $966.91 Million | 19.23% | 0.71x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $512.78 Million | -14.68% | 0.29x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $13.85 Billion | 7.86% | 0.18x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $428.60 Million | 11.05% | 0.37x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $29.65 Billion | 6.00% | 0.08x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $1.45 Billion | 1.65% | 0.22x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.05 Billion | 15.59% | 0.13x | $1.64 Billion |
About PharmaResources (Shanghai) Co. Ltd. A
PharmaResources (Shanghai) Co., Ltd. engages in new drug research, development, and commercial production in China. It offers small molecule drug CRO, CDMO, and CMO. The company also involved in drug discovery, research, and development of pharmaceutical processes; and customized and commercial production of APIs, and key intermediates. It serves global pharmaceutical and biotechnology companies.… Read more